Mild cognitive impairment associated with Alzheimer’s disease and Alzheimer’s disease itself.
Conditions
Interventions
experimental group:Take part in a 24-week computerised, multidisciplinary, adaptive training programme
control group:Take part in a 24-week fixed-format training programme
Sponsors
Sichuan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Age: 40-90 years (inclusive of 40 and 90 years), no gender restrictions; 2. Diagnostic criteria for Alzheimer’s disease according to the 2014 IWG-2 standard, CDR = 0.5 or CDR = 1; 3. Participants must have a primary or higher education level and be able to complete the cognitive ability assessments and other tests specified in the protocol; 4. Participants should have a stable and reliable caregiver who will assist them throughout the study. The caregiver must accompany the participant during the study follow-up and must engage in sufficient interaction and communication with the participant to provide valuable information for research-related questionnaires and scale assessments; 5. The patient or family member (caregiver) must sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Severe aphasia, visual impairment, or other conditions that may prevent completion of the neuropsychological assessment and completion of the computer-based cognitive training; 2. Severe underlying cardiovascular or pulmonary disease or hepatic or renal impairment or other conditions that may affect completion of cognitive function training; 3. Patients who have previously been diagnosed with an affective disorder (depression, anxiety disorder, schizophrenia, etc.); 4. Patients who plan to participate in another clinical trial within 30 days prior to or during the screening visit for this study; 5. Patients who have previously participated in a similar computer-based cognitive training program; 6. Patients who are unable to cooperate with the interviewer; 7. Patients who refuse to participate in the study; 8. Patients who are currently receiving treatment with lenacapone or Donanemab.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Functional magnetic resonance examination; | — |
Secondary
| Measure | Time frame |
|---|---|
| Audio-visual integration experiment;Changes in scores on various neuropsychological scales;Incidence of adverse events;Training adherence, patient dropout rate; | — |
Countries
China
Contacts
Public ContactQin Xiaohong
Sichuan Provincial People's Hospital
Outcome results
None listed